Psyence Group Inc. (PSYGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Psyence Group Inc. (PSYGF) trades at $0.14 with AI Score 48/100 (Grade C). Psyence Group Inc. is a life science biotechnology company focused on the cultivation, production, and development of psilocybin-based treatments. Market cap: $2.18M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for PSYGF: PSYGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PSYGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PSYGF: the 1 perspectives are evenly split.
How is this calculated? →Psyence Group Inc. (PSYGF) Healthcare & Pipeline Overview
Psyence Group Inc. is a biotechnology company specializing in the cultivation and development of psilocybin-based treatments for mental health disorders, alongside functional mushroom nutraceuticals. The company operates within the emerging psychedelic medicine market, focusing on addressing conditions like anxiety, depression, and PTSD.
What Is the Investment Thesis for PSYGF?
Psyence Group Inc. presents a speculative investment opportunity within the emerging psychedelic medicine market. The company's focus on developing psilocybin-based treatments for mental health disorders positions it to potentially benefit from the increasing acceptance and legalization of psychedelics for therapeutic purposes. Key value drivers include the successful development and clinical validation of its psilocybin formulations, expansion of its GOODMIND nutraceutical product line, and strategic partnerships. However, the company faces significant risks, including regulatory hurdles, competition from other companies in the psychedelic medicine space, and the need for substantial capital investment to fund its research and development activities. With a current P/E ratio of -0.12 and a Beta of 1.32, investors should carefully consider the high-risk, high-reward nature of this investment.
Based on FMP financials and quantitative analysis
PSYGF Key Highlights
- Psyence Group Inc. is focused on developing psilocybin-based treatments for mental health disorders, addressing a significant unmet need.
- The company cultivates and produces its own natural psilocybin, providing control over its supply chain and potentially reducing costs.
- Psyence is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders.
- The company also offers over-the-counter non-psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand, diversifying its revenue streams.
- Psyence Group Inc. was founded in 2019, positioning it as an early entrant in the emerging psychedelic medicine market.
Who Are PSYGF's Competitors?
PSYGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADXS Ayala Pharmaceuticals, Inc. | $0.60 | +0.00% | $25.71M | 43 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| SNYNF Sanofi | $85.25 | +0.64% | $102.48B | 48 |
| JCRRF JCR Pharmaceuticals Co., Ltd. | $3.31 | +5.25% | $403.80M | 48 |
| GIKLY Grifols, S.A. | $4.77 | -6.47% | $12.54B | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSYGF's Key Strengths?
- Early mover advantage in the emerging psychedelic medicine market.
- Proprietary cultivation and production methods for psilocybin mushrooms.
- Focus on addressing a significant unmet need in mental health treatment.
- Diversified revenue streams through psilocybin-based treatments and nutraceutical products.
What Are PSYGF's Weaknesses?
- Limited operating history and financial resources.
- Dependence on regulatory approvals for its psilocybin-based treatments.
- High level of competition in the pharmaceutical and nutraceutical industries.
- Lack of established distribution channels for its products.
What Could Drive PSYGF Stock Higher?
- Clinical trial results for psilocybin-based treatments for mental health disorders.
- Regulatory approvals for psilocybin-based treatments in key markets.
- Expansion of the GOODMIND nutraceutical product line.
- Strategic partnerships and collaborations with other companies.
- Increasing acceptance and legalization of psychedelics for therapeutic purposes.
What Are the Key Risks for PSYGF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Changes in regulations regarding psychedelic medicine.
- Competition from larger and more established pharmaceutical companies.
- Adverse side effects from its psilocybin-based treatments.
- Negative public perception of psychedelics.
- Limited operating history and financial resources.
What Are the Growth Opportunities for PSYGF?
- Expansion of Psilocybin-Based Treatment Programs: Psyence has the opportunity to expand its psilocybin-based treatment programs for mental health disorders. The market for mental health treatments is substantial, with the global market estimated to reach $533 billion by 2030. By developing and validating its psilocybin formulations, Psyence can capture a share of this market. This expansion depends on successful clinical trials and regulatory approvals, with a potential timeline of 3-5 years for commercialization.
- Growth of GOODMIND Nutraceutical Product Line: Psyence can leverage its GOODMIND brand to expand its nutraceutical product line. The global functional mushroom market is projected to reach $13.6 billion by 2028, driven by increasing consumer awareness of the health benefits of functional mushrooms. By introducing new and innovative products under the GOODMIND brand, Psyence can tap into this growing market. This expansion can be achieved within the next 1-2 years through product development and marketing efforts.
- Strategic Partnerships and Collaborations: Psyence can pursue strategic partnerships and collaborations with other companies in the pharmaceutical and biotechnology industries. These partnerships can provide access to new technologies, expertise, and resources, accelerating the development and commercialization of its products. Potential partners include pharmaceutical companies, research institutions, and mental health clinics. These partnerships can be established within the next 2-3 years.
- Geographic Expansion into New Markets: Psyence has the opportunity to expand its operations into new geographic markets, particularly in regions where regulations are becoming more favorable towards psychedelic medicine. This expansion can involve establishing new cultivation and production facilities, partnering with local distributors, or acquiring existing companies. Potential target markets include Europe, Australia, and South America. This expansion can be pursued over the next 3-5 years.
- Development of Novel Delivery Methods: Psyence can invest in the development of novel delivery methods for its psilocybin formulations. This can include developing new formulations that are easier to administer, have improved bioavailability, or provide more targeted delivery to the brain. Potential delivery methods include sublingual tablets, nasal sprays, and transdermal patches. The development of novel delivery methods can enhance the efficacy and patient acceptance of its treatments, providing a competitive advantage. This development can be pursued over the next 2-4 years.
What Opportunities Does PSYGF Have?
- Expansion into new geographic markets.
- Development of novel delivery methods for its psilocybin formulations.
- Strategic partnerships and collaborations with other companies.
- Increasing acceptance and legalization of psychedelics for therapeutic purposes.
What Threats Does PSYGF Face?
- Changes in regulations regarding psychedelic medicine.
- Competition from larger and more established pharmaceutical companies.
- Potential for adverse side effects from its psilocybin-based treatments.
- Negative public perception of psychedelics.
What Are PSYGF's Competitive Advantages?
- Proprietary cultivation and production methods for psilocybin mushrooms.
- Formulation expertise in developing psilocybin-based treatments.
- Established brand recognition for its GOODMIND nutraceutical products.
- Early mover advantage in the emerging psychedelic medicine market.
What Does PSYGF Do?
Founded in 2019 and based in Toronto, Canada, Psyence Group Inc. is a life science biotechnology company dedicated to the research, development, and commercialization of psilocybin-based treatments and functional mushroom products. The company's core focus is on addressing mental health disorders, including anxiety, depression, post-traumatic stress disorder (PTSD), and grief and bereavement, through the use of natural psilocybin. Psyence cultivates and produces psilocybin mushrooms, which are then used to develop pharmaceutical preparations of psilocybin doses. These preparations are intended to aid in healing psychological trauma and diagnosable disorders. In addition to its pharmaceutical endeavors, Psyence Group Inc. develops, distributes, and sells over-the-counter non-psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. This diversification allows the company to tap into the growing market for natural health and wellness products while continuing its research and development efforts in the psilocybin space. Psyence aims to be a leader in the emerging field of psychedelic medicine, providing innovative treatments for mental health conditions and contributing to the growing body of scientific knowledge in this area.
What Products and Services Does PSYGF Offer?
- Cultivates and produces psilocybin mushrooms.
- Develops pharmaceutical preparations of psilocybin doses.
- Conducts research on the therapeutic potential of psilocybin.
- Focuses on treating mental health disorders such as anxiety, depression, and PTSD.
- Develops, distributes, and sells over-the-counter functional mushroom nutraceutical products.
- Operates under the GOODMIND brand for its nutraceutical products.
How Does PSYGF Make Money?
- Develops and sells psilocybin-based treatments for mental health disorders.
- Generates revenue from the sale of functional mushroom nutraceutical products.
- Cultivates and produces its own psilocybin mushrooms, controlling the supply chain.
- Partners with research institutions and healthcare providers to advance its research and development efforts.
What Industry Does PSYGF Operate In?
Psyence Group Inc. operates within the rapidly evolving psychedelic medicine industry. This sector is characterized by increasing research into the therapeutic potential of psychedelic compounds like psilocybin, MDMA, and ketamine for treating mental health disorders. The market is driven by the growing prevalence of mental health conditions, the limitations of existing treatments, and changing regulatory attitudes towards psychedelics. Companies like Psyence are competing to develop and commercialize innovative psychedelic therapies, while also navigating complex regulatory pathways and addressing concerns about safety and efficacy. The industry is expected to experience significant growth in the coming years as more research is conducted and regulations evolve.
Who Are PSYGF's Key Customers?
- Individuals suffering from mental health disorders such as anxiety, depression, and PTSD.
- Healthcare providers who prescribe or administer psilocybin-based treatments.
- Consumers seeking natural health and wellness products.
- Research institutions and pharmaceutical companies interested in collaborating on research and development projects.
How Psyence Group Inc. Is Valued
Psyence Group Inc. carries a market capitalization of $2.18M, placing it in the micro-cap category. Relative to its peer group, PSYGF's quantitative score of 48/100 is below the peer average of 59/100.
Company Profile
Psyence Group Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Jody Aufrichtig. PSYGF has traded publicly since 2022.
ROE 304%Key Financial Metrics
Return on equity for Psyence Group Inc. stands at 303.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 16.88 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 3/9Financial Health
Psyence Group Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PSYGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Early mover advantage in the emerging psychedelic medicine market.
- Proprietary cultivation and production methods for psilocybin mushrooms.
- Focus on addressing a significant unmet need in mental health treatment.
- Diversified revenue streams through psilocybin-based treatments and nutraceutical products.
Bear Case
- Limited operating history and financial resources.
- Dependence on regulatory approvals for its psilocybin-based treatments.
- High level of competition in the pharmaceutical and nutraceutical industries.
- Lack of established distribution channels for its products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
PSYGF Latest News
-
Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
accessnewswire.com · May 21, 2026
PSYGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PSYGF.
Price Targets
Wall Street price target analysis for PSYGF.
PSYGF MoonshotScore
What does this score mean?
The MoonshotScore rates PSYGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jody Aufrichtig
CEO
Jody Aufrichtig is the CEO of Psyence Group Inc. His background includes experience in various sectors, including finance and entrepreneurship. He has a track record of building and scaling businesses, with a focus on innovation and growth. Aufrichtig's expertise lies in identifying emerging market opportunities and developing strategies to capitalize on them. He is passionate about the potential of psychedelic medicine to transform mental health treatment and is committed to leading Psyence Group Inc. in this endeavor.
Track Record: Under Jody Aufrichtig's leadership, Psyence Group Inc. has focused on developing and commercializing psilocybin-based treatments for mental health disorders. Key milestones include establishing cultivation and production facilities for psilocybin mushrooms, developing pharmaceutical preparations of psilocybin doses, and launching the GOODMIND nutraceutical product line. Aufrichtig has also overseen the company's research and development efforts, as well as its strategic partnerships and collaborations.
PSYGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Psyence Group Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited financial information available to the public, and trading in these stocks can be highly speculative. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are often early-stage ventures or those with distressed financials.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Difficulty in obtaining accurate and reliable financial information.
- Limited liquidity and wider bid-ask spreads.
- Verify the company's registration and compliance with securities laws.
- Review the company's financial statements and disclosures, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Focus on developing psilocybin-based treatments for mental health disorders.
- Development and sale of functional mushroom nutraceutical products under the GOODMIND brand.
- CEO with experience in finance and entrepreneurship.
- Company is based in Toronto, Canada.
Psyence Group Inc. Healthcare Stock: Key Questions Answered
What does Psyence Group Inc. do?
Psyence Group Inc. is a life science biotechnology company focused on the cultivation, production, and development of psilocybin-based treatments for mental health disorders. The company cultivates its own psilocybin mushrooms and develops pharmaceutical preparations of psilocybin doses. In addition to its pharmaceutical endeavors, Psyence develops, distributes, and sells over-the-counter non-psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand, targeting consumers seeking natural health and wellness solutions.
What do analysts say about PSYGF stock?
As of 2026-03-17, there is no readily available analyst coverage for PSYGF stock due to its OTC listing and early stage. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as revenue growth, profitability, and cash flow, should be carefully analyzed, along with the company's growth prospects and risk factors. The lack of analyst coverage highlights the speculative nature of this investment.
What are the main risks for PSYGF?
The main risks for Psyence Group Inc. include regulatory uncertainty surrounding psychedelic medicine, competition from larger pharmaceutical companies, potential adverse side effects from its psilocybin-based treatments, and negative public perception of psychedelics. Additionally, the company faces risks related to its limited operating history, financial resources, and dependence on regulatory approvals. As an OTC-listed company, PSYGF is subject to less stringent regulatory oversight and may have limited liquidity, increasing investment risk.
What are the key factors to evaluate for PSYGF?
Psyence Group Inc. (PSYGF) holds an AI score of 48/100 (low). Not financial advice.
How frequently does PSYGF data refresh on this page?
PSYGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PSYGF's recent stock price performance?
Psyence Group Inc. (PSYGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Early mover advantage in the emerging psychedelic medicine market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PSYGF overvalued or undervalued right now?
Valuing Psyence Group Inc. (PSYGF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PSYGF?
Before investing in Psyence Group Inc. (PSYGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company information and may be limited due to the company's OTC listing.
- AI analysis pending for PSYGF, which may provide additional insights.